Clinical trials: SARS
SARS-CoV-2 Infection
Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older
This is a Phase III, Randomized, Observer-Blind Study to Evaluate the Safety and Superiority in Immunogenicity of PTX-COVID19-B Administered as Booster Vaccination Compared to Vaxzevria® in Adults Aged 18 Years and Older Who Were…
- Trial name
- NCT05534035
- Testing
- PTX-COVID19-B, Vaxzevria®
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Everest Medicines (Singapore) Pte. Ltd.
COVID-19 Pandemic, COVID-19 Vaccines
UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)
The goal of this open-label clinical trial is to evaluate the safety and immunogenicity of INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) Vaccine as Homologue Booster in Adult Subjects in Indonesia.
- Conditions
- COVID-19 Pandemic, COVID-19 Vaccines, COVID-19 Virus Disease
- Trial name
- NCT06259578
- Testing
- INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg
- Where
- Indonesia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
Sars-CoV-2 Infection, Lung Fibrosis
Low-field Magnetic Resonance Imaging of Pediatric COVID-19
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a new coronavirus and identified causative agent of COVID-19 disease. They predominantly cause mild colds but can sometimes cause severe pneumonia.
- Conditions
- Sars-CoV-2 Infection, Lung Fibrosis, Covid19
- Trial name
- DECRYPT (NCT04990531)
- Testing
- Low-field magnetic resonance imaging, Blood sample
- Where
- Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School
COVID-19
A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
This is a phase Ⅰa, randomized, double-blind, positive control trial in healthy adults, intended to evaluate the safety and immunogenicity profile of RQ3013.
- Trial name
- NCT05394012
- Testing
- RQ3013, Comirnaty
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
SARS-CoV-2
Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People
Phase Ⅱ Clinical Trial to Evaluate the Safety and Immunogenicity of the New Coronavirus mRNA Vaccine (LVRNA009) in Chinese People Aged 18~59 Years
- Trial name
- NCT05352867
- Testing
- SARS-CoV-2 (LVRNA009) 50μg group, SARS-CoV-2 (LVRNA009) 100μg group
- Where
- 2 sites in China
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
SARS-CoV-2 Acute Respiratory Disease
A Prospective Virtual Study of Patient Reported Behaviors and Health Outcomes in Individuals With COVID-19
The primary objective of this study is to identify and describe patient behaviors and clinical outcomes among patients who have tested positive for mild to moderate COVID-19.
- Trial name
- NCT05042232
- Testing
- SARS-CoV-2 Positive, SARS-CoV-2 Negative
- Where
- United States
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Everly Health
COVID-19
A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults
This is an open-label, first-in-human, dose-finding study to evaluate the safety and immunogenicity of a booster vaccination of Prime-2-CoV_Beta in healthy participants.
- Trial name
- NCT05389319
- Testing
- Prime-2-CoV_Beta
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
SARS-CoV-2 Infection
A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine
A randomised, blinded, parallel-controlled phase 1 clinical trial to evaluate the safety and preliminary immunogenicity of a COVID-19 mRNA vaccine in a healthy population aged 18 years and older, and to investigate immunisation…
- Trial name
- NCT06113744
- Testing
- COVID-19 Vaccine (Vero Cell) ,Inactivated, COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg, COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg
- Where
- China
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
Pandemics
Conversational Agent Vaccine Promotion RCT
The objective of this study is to assess the use of and satisfaction with the ECA intervention over a 12-month period, its ability to increase SARS-CoV-2 and influenza vaccination in the BMATP community, and the comparative…
- Trial name
- NCT04884750
- Testing
- ECA-ACE Vaccination Promotion Intervention
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Northeastern University
Covid19, Severe Acute Respiratory Syndrome
Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)
This phase 1 trial aims to assess the safety and tolerability of two doses of ABNCoV2, formulated with and without the adjuvant MF59, in healthy adult volunteers and to identify the dosage and formulation that optimizes the…
- Conditions
- Covid19, Severe Acute Respiratory Syndrome, SARS-CoV-2 Infection
- Trial name
- COUGH-1 (NCT04839146)
- Testing
- ABNCoV2 Vaccine
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Anti-SARS-CoV-2 Antibody Response
Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines
The investigators aim to evaluate the ability of a COVID-19 (Coronavirus disease) booster vaccine to induce a salivary antibody response and investigate a possible correlation with the serum antibody response and the cellular…
- Trial name
- CoVVacBoost (NCT05142540)
- Testing
- blood and saliva samples will be taken
- Where
- Austria
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
COVID-19 Virus Disease
Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease.
A Phase I dose-escalation study to test a new monoclonal antibody (called MAD0004J08) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 disease.
- Trial name
- MAD0004J08 (NCT04932850)
- Testing
- MAD0004J08
- Where
- 2 sites in Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Toscana Life Sciences Sviluppo s.r.l.
Healthy Adult Volunteers
Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination
The investigators conduct a prospective analysis to compare homologous and heterologous adenovirus vector ChAdOx1-nCov-19 (Astra-Zeneca) or SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine inoculation.
- Trial name
- NCT05074368
- Testing
- ChAdOx1-nCov-19 (Astra-Zeneca), SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
- Where
- Taiwan
- Volunteers
- 499 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
SARS-CoV2 Infection
Evaluation of the Sofia SARS Antigen FIA Assay for COVID-19
Evaluating the performance of the Sofia SARS Antigen FIA
- Trial name
- ESADEC (NCT04953091)
- Where
- 2 sites in France
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
COVID-19 Pandemic, COVID-19 Vaccines
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)
This is an observer blind randomized controlled trial study to evaluate the humoral immunogenicity profile - neutralizing antibody - after 28 days following vaccination with Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell…
- Trial name
- NCT05918939
- Testing
- Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg, CoronaVac Biofarma COVID-1 9 Vaccine 3 µg
- Where
- Indonesia
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
COVID-19
Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
This is a phase I, single-center, randomized, placebo-controlled, double-blind study, to evaluate safety, tolerability and immunogenicity of a recombinant SARS-CoV-2 vaccine (Sf9 cell) in Chinese healthy population aged 18 years…
- Trial name
- NCT04530656
- Testing
- Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28, Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28, Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28
- Where
- China
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
COVID-19, SARS-CoV-2
Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)
The primary objective is to assess the safety and tolerability of samRNA vaccines GRT-R912, GRT-R914, and GRT-R918 when administered as prime and/or boost in healthy adult participants naïve to severe acute respiratory syndrome…
- Trial name
- NCT05435027
- Testing
- GRT-R912, samRNA-Spikebeta-TCE11, GRT-R914, samRNA-Spikebeta-TCE9, GRT-R918, samRNA-SpikeOmicron-N-TCE11
- Where
- 4 sites in South Africa
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Gritstone bio, Inc.
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.
- Trial name
- IST (NCT05018975)
- Testing
- Tazemetostat
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University
SARS-CoV-2 Infection, Covid19
Tobacco Use and COVID-19 Incidence in the Finnish General Population
This is an observational study of participants in three general population health surveys (FinSote 2018, 2019, 2020) who are followed up until the incidence of SARS-CoV-2 infection or end of follow-up.
- Trial name
- Tobrisk-CoV (NCT04915781)
- Testing
- Not applicable, this is an observational study
- Where
- Finland
- Volunteers
- 60,872 people, healthy volunteers welcome
- Sponsor
- Finnish Institute for Health and Welfare
Healthy Participants
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.
This study is to characterize mass balance and further the understanding of human pharmacokinetics, metabolism, and excretion of radiolabeled [14C]PF-07321332 in healthy male participants following oral administration with…
- Trial name
- NCT05178654
- Testing
- [14C]PF-07321332
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.